Adamas announces issuance of new patents for gocovri and ads-4101

Emeryville, calif.--(business wire)--adamas pharmaceuticals, inc. (nasdaq: adms), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announces the issuance of two patents covering gocovri® (amantadine) extended-release capsules: u.s. patent no. 11,065,213 issued on july 20, 2021, and u.s. patent no. 11,077,073, projected to issue on august 3, 2021. these two patents are the first issued in this patent f
ADMS Ratings Summary
ADMS Quant Ranking